Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?
Related Questions
How do you use P1NP in your clinical practice to guide management of osteoporosis?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
What is your approach to management of methotrexate osteopathy?
When considering pharmacologic treatments recommended by the 2022 glucocorticoid induced osteoporosis guidelines, do you use NNT/NNH to select between each treatment option by risk categories (e.g., moderate, high, very high)?
What is your approach to management of severe osteoporosis in patients with advanced kidney disease?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Is elevated bone specific alkaline phosphatase an absolute contraindication to teriparatide?
